Prasanna Xavier, Chattopadhyay Amitabha, Sengupta Durba
CSIR-National Chemical Laboratory, Pune, India.
CSIR-Centre for Cellular and Molecular Biology, Hyderabad, India.
Biophys J. 2014 Mar 18;106(6):1290-300. doi: 10.1016/j.bpj.2014.02.002.
The β2-adrenergic receptor is an important member of the G-protein-coupled receptor (GPCR) superfamily, whose stability and function are modulated by membrane cholesterol. The recent high-resolution crystal structure of the β2-adrenergic receptor revealed the presence of possible cholesterol-binding sites in the receptor. However, the functional relevance of cholesterol binding to the receptor remains unexplored. We used MARTINI coarse-grained molecular-dynamics simulations to explore dimerization of the β2-adrenergic receptor in lipid bilayers containing cholesterol. A novel (to our knowledge) aspect of our results is that receptor dimerization is modulated by membrane cholesterol. We show that cholesterol binds to transmembrane helix IV, and cholesterol occupancy at this site restricts its involvement at the dimer interface. With increasing cholesterol concentration, an increased presence of transmembrane helices I and II, but a reduced presence of transmembrane helix IV, is observed at the dimer interface. To our knowledge, this study is one of the first to explore the correlation between cholesterol occupancy and GPCR organization. Our results indicate that dimer plasticity is relevant not just as an organizational principle but also as a subtle regulatory principle for GPCR function. We believe these results constitute an important step toward designing better drugs for GPCR dimer targets.
β2肾上腺素能受体是G蛋白偶联受体(GPCR)超家族的重要成员,其稳定性和功能受膜胆固醇调节。最近β2肾上腺素能受体的高分辨率晶体结构揭示了该受体中可能存在胆固醇结合位点。然而,胆固醇与该受体结合的功能相关性仍未得到探索。我们使用MARTINI粗粒度分子动力学模拟来探究含胆固醇的脂质双层中β2肾上腺素能受体的二聚化。我们的结果有一个(据我们所知)新颖之处,即受体二聚化受膜胆固醇调节。我们表明胆固醇与跨膜螺旋IV结合,该位点的胆固醇占据限制了其在二聚体界面的参与。随着胆固醇浓度增加,在二聚体界面观察到跨膜螺旋I和II的存在增加,但跨膜螺旋IV的存在减少。据我们所知,本研究是最早探索胆固醇占据与GPCR组织之间相关性的研究之一。我们的结果表明,二聚体可塑性不仅作为一种组织原则,而且作为GPCR功能的一种微妙调节原则都具有相关性。我们相信这些结果是朝着为GPCR二聚体靶点设计更好的药物迈出的重要一步。